biotech · Respiratory Distress Syndrome · Cardiogenic Shock · WINT
WINDTREE THERAPEUTICS INC
WINDTREE THERAPEUTICS INC /DE/
Windtree Therapeutics is a biotech organization headquartered in Warrington, USA. It trades on NYSE under ticker WINT. Primary therapeutic focus areas include Respiratory Distress Syndrome, Cardiogenic Shock, Respiratory
2600 Kelly Rd., Suite 100, Warrington, PA 18976, US HQ
1992 Founded
17 Employees
Public company Type
WINT · NYSE Ticker
Company details
- Status
- Public
- HQ
- 2600 Kelly Rd., Suite 100, Warrington, PA 18976, US
- Founded
- 1992
- Employees
- 17
- Programs
- 15
- Drugs
- 9
- Patents
- 4
Lucinactant 175 mg/kg
Phase 2 · small molecule · Respiratory Distress Syndrome, Newborn
Lucinactant 175 mg/kg for Respiratory Distress Syndrome, Newborn is a Phase 2 program (small_molecule) at WINDTREE THERAPEUTICS INC /DE/ with 1 ClinicalTrials.gov record(s).
Internal code KL4-BPD-01
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- WINDTREE THERAPEUTICS INC /DE/
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Respiratory Distress Syndrome, Newborn
- Status
- terminated
- Trials
- 1